Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton Acquires 200,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton bought 200,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the acquisition, the chief financial officer now owns 200,000 shares in the company, valued at $112,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Lyell Immunopharma Stock Performance

Shares of LYEL opened at $0.53 on Friday. The firm has a market capitalization of $157.45 million, a P/E ratio of -0.68 and a beta of -0.41. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15. The stock has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $0.89.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.01 million for the quarter. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

Several institutional investors and hedge funds have recently made changes to their positions in LYEL. Centiva Capital LP bought a new stake in Lyell Immunopharma in the 3rd quarter worth about $31,000. Graham Capital Management L.P. bought a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $33,000. RPO LLC bought a new position in shares of Lyell Immunopharma in the fourth quarter valued at approximately $42,000. Intech Investment Management LLC purchased a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Lyell Immunopharma during the third quarter worth $52,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.